Becton, Dickinson and Company $BDX Shares Sold by EagleClaw Capital Managment LLC

Key Points

• EagleClaw Capital Management cut its Becton, Dickinson and Company stake by 29.4% in the fourth quarter, selling 9,445 shares and leaving it with 22,671 shares valued at about $4.4 million.
• Analyst sentiment is mixed: several firms lowered price targets, and MarketBeat shows a consensus rating of “Hold” with an average target price of $183.64.
• BDX beat earnings expectations in its latest quarter, reporting EPS of $2.90 versus $2.77 expected, while revenue rose 5.2% year over year to $4.71 billion; the company also declared a quarterly dividend of $1.05 per share.

EagleClaw Capital Managment LLC lessened its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 29.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,671 shares of the medical instruments supplier's stock after selling 9,445 shares during the period. EagleClaw Capital Managment LLC's holdings in Becton, Dickinson and Company were worth $4,400,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of BDX. Wellington Management Group LLP boosted its stake in Becton, Dickinson and Company by 9,056.3% in the third quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier's stock valued at $979,290,000 after acquiring an additional 5,174,944 shares in the last quarter. Vanguard Group Inc. boosted its stake in Becton, Dickinson and Company by 13.0% in the fourth quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier's stock valued at $7,118,282,000 after acquiring an additional 4,223,149 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in Becton, Dickinson and Company by 23,219.2% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier's stock valued at $769,397,000 after acquiring an additional 4,137,888 shares in the last quarter. First Eagle Investment Management LLC boosted its stake in Becton, Dickinson and Company by 16.5% in the fourth quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier's stock valued at $2,260,139,000 after acquiring an additional 1,651,592 shares in the last quarter. Finally, Veritas Asset Management LLP boosted its stake in Becton, Dickinson and Company by 40.6% in the third quarter. Veritas Asset Management LLP now owns 2,954,898 shares of the medical instruments supplier's stock valued at $553,068,000 after acquiring an additional 852,854 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on BDX shares. The Goldman Sachs Group decreased their price objective on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a "neutral" rating for the company in a research note on Wednesday. Stifel Nicolaus decreased their price objective on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a research note on Thursday, May 7th. Argus decreased their price objective on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a "buy" rating for the company in a research note on Monday, March 23rd. Zacks Research upgraded shares of Becton, Dickinson and Company from a "strong sell" rating to a "hold" rating in a research note on Friday, April 10th. Finally, Wells Fargo & Company increased their target price on shares of Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an "equal weight" rating in a research note on Friday, May 8th. Seven investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $183.64.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $148.36 on Friday. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The company has a market capitalization of $40.88 billion, a price-to-earnings ratio of 37.56, a price-to-earnings-growth ratio of 10.42 and a beta of 0.22. The firm has a 50-day simple moving average of $151.84 and a 200-day simple moving average of $177.23. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The business had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.67 billion. During the same quarter in the prior year, the firm earned $3.35 earnings per share. The business's quarterly revenue was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, equities research analysts anticipate that Becton, Dickinson and Company will post 12.61 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company's dividend payout ratio is currently 106.33%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.